Long-acting injectable antiretroviral therapy for HIV-1 infection in adults

Long-acting injectable antiretroviral therapy for HIV-1 infection in adults Practice | Five things to know about ... [...] CPD Long-acting injectable antiretroviral therapy for HIV-1 infection in adults Sheliza Halani MD, Darrell Tan MD PhD,* Nisha Andany MD MPH* n Cite as: CMAJ 2024 March 18;196:E341-2. [...] doi: 10.1503/cmaj.231498 1 HIV-1 can be successfully treated with long-acting injectable antiretroviral therapy A dual regimen combining the integrase strand transfer inhibitor cabotegravir with the nonnucleoside reverse transcriptase inhibitor rilpivirine1 is the first complete long-acting, injectable, antiretroviral regimen for adults living with HIV-1.2,3 Randomized trials have shown noninferio. [...] Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. [...] Content licence: This is an Open Access article distributed in accord ance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and repro- duction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educa- tional use), and no modifications or adaptations are made.